Paradigm Therapeutics Secures $12.5 Million Investment for Innovative EB Treatment Development

Paradigm Therapeutics Secures Funding for EB Treatment Development

Paradigm Therapeutics, Inc., an innovative biopharmaceutical company, recently revealed that it has successfully secured a $12.5 million investment from Eshelman Ventures, LLC. This strategic infusion of capital is aimed at propelling the development of SD-101, also known as Zorblisa™, designed to treat Epidermolysis Bullosa (EB) across all its subtypes. This funding comes at a critical time, as the company gears up for a New Drug Application (NDA) submission planned for the latter half of 2025.

Epidermolysis Bullosa is a rare genetic disorder characterized by severe skin fragility and blistering, often beginning at birth. Patients with this condition experience debilitating symptoms that can lead to chronic wounds and the need for extensive care. Currently, there are no approved treatments that effectively address the entire skin surface for all subtypes of EB, highlighting the urgent need for effective therapeutic options.

Dr. Robert Ryan, CEO of Paradigm Therapeutics, expressed enthusiasm for the opportunity this funding presents, stating, "We are excited about the opportunity to complete the development activities for Zorblisa™ and to move a path forward towards registration of this therapy for patients with all EB subtypes." He emphasized the considerable need for comprehensive treatment solutions for EB patients, who all too often face limited options for managing their condition.

Studies conducted thus far have shown promising results for Zorblisa™. The therapy was tested in Phase II and Phase III trials, demonstrating positive effects on the healing of wounds and lesions for both pediatric and adult patients suffering from various forms of Epidermolysis Bullosa. The clinical findings suggest that Zorblisa™ is not only beneficial for skin repair but also maintains a favorable safety profile for long-term use.

Dr. Eshelman, founder of Eshelman Ventures, has joined Paradigm as a strategic advisor and expressed his commitment to the initiative: “Eshelman Ventures is honored to invest in Paradigm Therapeutics and play a pivotal role in accelerating the development of SD-101 as a transformative treatment for Epidermolysis Bullosa.” He further remarked on the urgent need to address the challenges faced by EB patients, aiming to improve their quality of life through better treatment options.

What Is Epidermolysis Bullosa?

Epidermolysis Bullosa (EB) encompasses several subtypes, all sharing the common characteristic of extremely fragile skin. The blisters and wounds can result from minor friction or trauma, making daily life challenging for those affected. Currently, there is no effective solution that comprehensively treats all these subtypes, which also include life-threatening variations.

Zorblisa™ - A Promising Solution

Zorblisa™ emerged as the first topical therapy for EB to receive Breakthrough Therapy designation from the FDA. Furthermore, it has earned designations for both Rare Pediatric Disease and Orphan Drug statuses, underscoring the FDA's recognition of the therapy's potential impact on patients with limited options.

The clinical trials involving a total of 217 EB patients demonstrated Zorblisa™'s ability to significantly aid in wound healing and overall skin care. The simplicity of its application—a topical cream that can be stored at room temperature—makes it an accessible treatment for patients, thus showing promise for widespread use across diverse patient demographics.

Paradigm Therapeutics remains focused on advancing this innovative therapy for global patient access. With strategic plans on partnerships and commercialization efforts in the pipeline, the company aims to navigate the regulatory landscape efficiently while prioritizing the health and needs of EB patients.

In summary, the $12.5 million investment signifies a beacon of hope for individuals affected by Epidermolysis Bullosa, heralding a new era in treatment possibilities. As Paradigm Therapeutics continues its journey, the focus remains on turning promising research into tangible results for those enduring this challenging condition.